Orphan Drug Status Goes to Engineered T-Cell Product
The U.S. Food & Drug Administration has awarded Orphan Drug Status to Kite Pharma for the company's engineered T-cell product.
Kite Pharma's engineered T-cell product is designed to treat difficult-to-treat cases of diffuse large B-cell lymphoma. This is an autologous T-cell, meaning it is contributed by the patient and then engineered in a laboratory before being returned to the patient.
Company aims for 'Holy Grail' of cancer treatment
In this case, Kite Pharma's engineering teaches the T-cells to target CD19 protein expression on the surface of B-cell lymphocytes and to kill them, effectively enlisting the body's own immune system to fight cancer – a goal considered by many to be the Holy Grail of cancer treatment.
Kite Pharma was launched five years ago, in 2009. They have been part of a cooperative research and development agreement with the National Cancer Institute's surgery branch to develop this Chimeric Antigen Receptor CD19 technology.
A pair of studies presented at the ASH conference in December showed the potential efficacy of the treatment in a handful of DLBCL patients.
Source: Healio
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
